

Curriculum Vitae

Personal information **Peter Vuylsteke**

Work experience

PROFESSIONAL AND TEACHING EXPERIENCE

2025- to date: Clinical Professor, Vrije Universiteit Brussel, Brussels, Belgium
Professor (Honorary position), University of Botswana, Botswana

2024- to date: Head of Department, Oncology, Brugmann University Hospital, Vrije Universiteit Brussel, Brussels, Belgium

2021-2024 : Head of Department, Internal Medicine, University of Botswana (UB) and Princess Marina hospital
□ Coordinating department of 22 specialist physicians, 6 hospitalist doctors, 6 interns and 20 Mmed Internal Medicine residents

2020- to date: Research Associate, Botswana Harvard Partnership (BHP), Botswana

2019-2024 : Senior Lecturer, Internal Medicine and Oncology, UB, Botswana:

- Teaching Oncology and Hematology: 2-weekly Patient Based Learning (PBL) and Bedside teachings for Undergraduate and Postgraduate students
- Lecture on Cancer development for 2nd year medical students. (3 hours)
- Student coordinator for 4th year Medical students (2019/2021)
- Coordination of Virtual teaching tumor Boards (BOTSOGO tumorboard, joint remotely by MGH Harvard Faculty)
- Coordinator for the Internal Medicine Morning report teachings (3*/week)
- Mmed (Masters) and Phd thesis supervision : 4 completed, 6 ongoing
- Curriculum development and training:
 - a Case-based Training Program for Oncologic Emergencies in Botswana (10 sessions, 15 hours)
 - Cancer Kitso: a course on learning the Basics of Cancer care for non-oncologists (8 modules, 20 hours)
 - Navigation course on breast cancer, training nurse navigators and non-clinical peer navigators.(4 modules, 10 hours)

Consultant Medical Oncologist, Princess Marina hospital, Botswana:

Global Oncology Outreach facilitator, Rutgers-Botswana Partnership for Health, NJ, USA:

- National Cancer Plan elaboration, Rutgers-UB-NHL Pathology working group, Patient Navigation program for Breast Cancer

Upenn collaborator

Research on expediting early diagnosis of Cervical Cancer and on HPV Viral load evolution under Radiotherapy in PLWHIV

2011-2019: Hemato-Oncology Head of department, CHU UCL Namur Site Sainte Elisabeth Namur, Belgium.

- Management of a team of 11 doctors + 5 research coordinators of the clinical trial unit.

2005-2019: Medical Oncologist, CHU UCL Namur/ Site Sainte Elisabeth, Namur, Belgium.

2000-2004: Resident UZ Gasthuisberg, KULeuven, Belgium (Medical Oncology from 2002).

1999-2000: Resident Hammersmith Hospital London, Imperial College, NHS, UK.

1998-1999: Resident St-Elisabeth Hospital Turnhout, Belgium.

1996-1997 Internship: medical training program in Belgium and South-Africa (Tygerberg Hospital Cape Town and Kalafong Hospital, Pretoria).

Education and training

Sept 2017: ESMO Leaders Generation Award (Academic leadership)

July 2005: Specialist degree in Internal Medicine and Medical Oncology, KULeuven, Belgium.

June 1998: Medical Physician Degree KULeuven, Belgium.

1994-1998: Medical studies KUL Leuven, High Honors (Magna Cum Laude)

1991-1994: Medical studies FUNDP Namur, High Honors (Magna Cum Laude)

1985-1991: Classical Humanities (Latin-Greek), H-Hart-College, Waregem, Belgium

Additional information

Publications

1. Vuylsteke P, Knockaert DC, Blockmans D, Arnaut J, Vanderschueren S. Abdominal pain, hypertension, and thrombocytopenia. The Lancet. 2003 Nov 22;362(9397):1720.
2. Vuylsteke P, Bertrand C, Verhoef G, Vandenbergh P. Megaloblastic anaemia caused by intestinal taeniasis. Ann Hematol. 2004 Jul; 83(7):487-8.
3. Wildiers H, Fontaine C, Vuylsteke P, Martens M, Canon JL, Wynendaele W, Focan C, De Greve J, Squifflet P, Paridaens R. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2010 Sep;123(2):463-9.
4. Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S,

- Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart M, Sotiriou C. Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer. *PLoS One*. 2013 Aug 19;8(8)
5. Gebhart G, Gámez C, Holmes E, Robles J, García C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart M, Flamen P, Di Cosimo S. 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO. *J Nucl Med*. 2013 Oct 3.
 6. Azim HA, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M. Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial. *Breast*. 2013 Sep 20.
 7. Azim HA Jr, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger JG Jr, Smith I, Jackisch C, Kim SB, Aktas B, Huang CS, Vuylsteke P, Hsieh RK, Dreosti L, Eidtmann H, Piccart M, de Azambuja E. Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy : Analyses From the NeoALTTO Trial. *J. Clin Oncol*. 2013 Nov 18
 8. Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. *Lancet Oncol*. 2014 Aug 14. pii: S1470-2045(14)70320-1.
 9. Mardjuali FI, Carrasco J, Coche JC, Sempoux C, Jouret-Mourin A, Scalliet P, Goeminne JC, Daisne JF, Delaunoy T, Vuylsteke P, Humblet Y, Meert N, van den Eynde M, Moxhon A, Haustermans K, Canon JL, Machiels JP. Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer. *Target Oncol*. 2014 Oct 11
 10. Bonnefoi H, Jacot W, Saghachian M, Moldovan C, Venat-Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, Tredan O, Messina CG, Slaets L, Cameron D. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. *Annals of Oncology*. 2014 Dec 1
 11. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Spaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. *Lancet Oncol*. 2014 Dec 3. pii: S1470-2045(14)71135-0.
 12. Jacques De Grève, Teresa Moran, Marie-Pascale Graas, Daniella Galdermans, Peter Vuylsteke, Jean-Luc Canon, Denis Schallier, Lore Decoste, Erik Teugels, Dan Massey. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. *Lung Cancer*, Jan 2015
 13. Ignace Vergote, Philip Debruyne, Frédéric Kridelka, Patrick Berteloot, Frédéric Amant, Brigitte Honhon, Willem Lybaert, Karin Leunen, Kurt Geldhof, Didier Verhoeven, Frédéric Forget, Peter Vuylsteke, Lionel D'Hondt, Manon Huizing, Heidi Van den Bulck, nouchka Laenen. Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group. *Gynecologic Oncology*, 2015.
 14. Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, Debrock G, Van Den Bulck H, Smeets A, Bechter O, Kini Bailur J, Kenis C, Laenen A, Schöffski P, Pawelec G, Journe F, Ghanem GE, Wildiers H. The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. *Oncotarget*. 2016 Apr 18. doi: 10.18632/oncotarget.8796.
 15. De Grève J, Van Meerbeeck J, Vansteenkiste JF, Decoster L, Meert AP, Vuylsteke P, Focan C, Canon JL, Humblet Y, Berchem G, Colinet B, Galdermans D, Bosquée L, Vermeij J, Dewaele A, Geers C, Schallier D, Teugels E. Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). *PLoS One*. 2016 Mar 31;11(3):e0147599. doi: 10.1371/journal.pone.0147599.
 16. Husain A, Wang Y, Hanker LC, Ojeda B, Anttila M, Breda E, Vuylsteke P, Pujade-Lauraine E. Independent Radiologic Review of AURELIA, A Phase 3 Trial of Bevacizumab Plus Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer. *Gynecol Oncol*. 2016 May 13. pii: S0090-8258(16)30730-2. doi: 10.1016/j.ygyno.2016.05.011.
 17. Vuylsteke P; M. Huizing; K. Petrakova; R. Roylance; R. Laing; S. Chan; F. Abell; S. Gendreau; I. Rooney; D. Apt; J. Zhou; S. Singel; L. Fehrenbacher. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. *Annals of Oncology*. 2016 Nov;27(11):2059-2066.
 18. Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Goulinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghachian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med*. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.
 19. Pulford DJ, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox C, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A. Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. *BMC Med Ethics*. 2016 Oct 21;17(1):63.
 20. Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trabectedin or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. *Eur J Cancer*. 2016 Nov 30;70:111-121. doi: 10.1016/j.ejca.2016.09.004.
 21. Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. *Breast Cancer Res Treat*. 2017 Mar 21. doi: 10.1007/s10549-017-4199-3
 22. Vuylsteke P, MD, Goeminne JC, MD, Henry S, MD, Vanhaudenarde V, MD, Willemart B, MD, Marchettini P, MD, Taylor D, MD. Should Tumour Infiltrating Lymphocytes and PIK3Ca mutation be added as markers to the histology report for breast cancer? *Belgian Journal of Medical Oncology*, Feb 2017, 11(5): 7-9
 23. José Baselga, Seock-Ah Im, Hiroji Iwata, Javier Cortés, Michele De Laurentiis, Zefei Jiang, Carlos L Arteaga,

Walter Jonat, Mark Clemons, Yoshinori Ito, Ahmad Awada, Stephen Chia, Agnieszka Jagiello-Gruszfeld, Barbara Pistilli, Ling-Ming Tseng, Sara Hurvitz, Norikazu Masuda, Masato Takahashi, Peter Vuylsteke, Soulef Hachemi, Bharani Dharan, Emmanuelle Di Tomaso, Patrick Urban, Cristian Massacesi, Mario Campone. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*, 30 May 2017, doi: 10.1016/S1470-2045(17)30376-5

24. Quinten C, Kenis C, Hamaker M, Coolbrandt A, Brouwers B, Dal Lago L, Neven P, Vuylsteke P, Debrock G, Van Den Bulck H, Smeets A, Schöffski P, Bottomley A, Wedding U, Wildiers H. The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥ 70 with early stage invasive breast cancer. *J Geriatr Oncol*. 2017 Nov 19. pii: S1879-4068(17)30213-8. doi: 10.1016/j.jgo.2017.10.001.

25. Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné AS, Brouckaert O, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentje V, Van Calster B, Guchelaar HJ. Tamoxifen metabolism and efficacy in breast cancer- a prospective multicentre trial. *Clin Cancer Res*. 2018 Feb 19. pii: clincanres.3028.2017. doi: 10.1158/1078-0432.CCR-17-3028.

26. Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Altintas S, Touati N, Cardoso F, Brain E. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. *Lancet Oncol*. 2018 Feb 9. pii: S1470-2045(18)30083-4. doi: 10.1016/S1470-2045(18)30083-4.

27. Ignatiadis M, Litière S, Rothe F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart M, Sotiriou C, Rack B, Pierga JY. Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial. *Ann Oncol*. 2018 Jun 11. doi: 10.1093/annonc/mdy211.

28. Verhoeven D, Duhoux FP, de Azambuja E, Wildiers H, Vuylsteke P, Barbeaux A, Van Damme N, Van Eycken E. Quality management for systemic treatment of breast cancer. *Belgian Journal of medical Oncology*, 2018;12;15-21

29. Fontaine C, Renard V, Van den Bulk H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, Vanacker L, de Azambuja E, De Greve J, Awada A, Wildiers H. Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO). *Breast Cancer Res Treat*. 2019 May 8. doi: 10.1007/s10549-019-05259-z.

30. Tuyaerts S, Van Nuffel AMT, Naert E, Van Dam PA, Vuylsteke P, De Caluwé A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, Amant F, Vandecasteele K, Denys H. PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. *BMC Cancer*. 2019 May 28;19(1):506. doi: 10.1186/s12885-019-5676-3. PMID:31138229

31. Fontaine C, Claes N, Graas MP, Samani KK, Vuylsteke P, Vulsteke C. Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg. *Acta Clin Belg*. 2019 Aug 9;1-6. doi: 10.1080/17843286.2019.1646539.

32. Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol*. 2019 Aug 8. pii: S1470-2045(19)30334-1.

33. Feys T, Vuylsteke P. Highlights in gynaecological cancers, *BJMO (Belgian Journal of Medical Oncology)*. 2019 Aug; 13(5): 204-209

34. Delalogue S, Piccart M, Rutgers E, Litière S, van 't Veer LJ, van den Berkmoortel F, Brain E, Dudek-Peric A, Gil-Gil M, Gomez P, Hilbers FS, Khalil Z, Knox S, Kuemmel S, Kunz G, Lesur A, Pierga JY, Ravdin P, Rubio IT, Saghachian M, Smilde TJ, Thompson AM, Viale G, Zoppoli G, Vuylsteke P, Tryfonidis K, Poncet C, Bogaerts J, Cardoso F; MINDACT investigators and the TRANSBIG Consortium. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. *J Clin Oncol*. 2020 Feb 21;JCO1901371.

35. Van Marcke C, Helaers R, De Leener A, Merhi A, Schoonjans CA, Ambroise J, Galant C, Delrée P, Rothé F, Bar I, Khoury E, Brouillard P, Canon JL, Vuylsteke P, Machiels JP, Berlière M, Limaye N, Vikkula M, Duhoux FP. Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families. *Breast Cancer Res*. 2020 Apr 15;22(1):36.

36. Quinten C, Kenis C, Hamaker M, Coolbrandt A, Brouwers B, Dal Lago L, Neven P, Vuylsteke P, Debrock G, Van Den Bulck H, Smeets A, Schöffski P, Wedding U, Wildiers H. The added value of geriatric assessment in evaluating a patient's Health-Related Quality-of-Life: A study in ≥ 70 -year-old early-stage invasive breast cancer patients. *H.Eur J Cancer Care (Engl)*. 2020 Jun 18:e13278.

37. Rasschaert M, Vulsteke C, De Keersmaeker S, Vandenborne K, Dias S, Verschaeve V, Vuylsteke P, Brussel IV, Ravelingien J, Dam PV, Segelov E, Peeters AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients. *M.Support Care Cancer*. 2020 Jun 9

38. Boeckx B, Shahi RB, Smeets D, De Brakeleer S, Decoster L, Van Brussel T, Galdermans D, Vercauter P, Decoster L, Alexander P, Berchem G, Ocaik S, Vuylsteke P, Deschepper K, Lambrechts M, Cappoen N, Teugels E, Lambrechts D, De Greve J. The genomic landscape of non-small cell lung carcinoma in never smokers. *Int J Cancer*. 2020 Jun 1;146(11):3207-3218.

39. Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehoul J, O'Malley DM, Churrua C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I.

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. *J Clin Oncol*. 2020 Aug 21;JCO2001164.

40. Derksen JW, Warren GW, Jordan K, Rauh S, Vera García R, O'Mahony D, Ahmed S, Vuylsteke P, Radulovic S, Tsoukalas N, Wysocki PJ, Borner M, Cesas A, Elme A, Minn H, Ullenhag GJ, Roodhart JML, Koopman M, May AM. European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment. *Eur J Cancer*. 2020 Aug 29;138:99-108. doi: 10.1016/j.ejca.2020.07.020.

41. de Azambuja E, Brandão M, Wildiers H, Laenen A, Aspeslagh S, Fontaine C, Collignon J, Lybaert W, Verheezen J, Rutten A, Vuylsteke P, Goeminne JC, Demey W, Van Beckhoven D, Deblonde J, Rottey S, Geukens T, Punie K;

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. Belgian Collaborative Group on COVID-19 Hospital Surveillance and the Belgian Society of Medical Oncology (BSMO).ESMO Open. 2020 Sep;5(5)

42. Ubachs J, Koole SN, Lahaye M, Fabris C, Bruijs L, Schagen van Leeuwen J, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham M, van Dam P, Vuylsteke P, Bastings J, Kruitwagen RFP, Lambrechts S, Olde Damink SWM, Rensen SS, Van Gorp T, Sonke GS, van Driel WJ. No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study. *Gynecol Oncol*. 2020 Oct 2:S0090-8258(20)33952-4.

43. Vergote I, Denys H, De Greve J, Gennigens C, Van De Vijver K, Kerger J, Vuylsteke P, Baurain JF. Treatment algorithm in patients with ovarian cancer. *Facts Views Vis Obgyn*. 2020 Oct 8;12(3):227-239

44. Koole SN, Bruijs L, Fabris C, Sikorska K, Engbersen M, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, van der Velden J, Arts HJG, van Ham M, Van Dam P, Vuylsteke P, Lahaye M, Sonke G, Driel WV. Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer. *Int J Gynecol Cancer*. 2020 Oct 12:ijgc-2020-001825..

45. Gómez-Aleza C, Nguyen B, Yoldi G, Ciscar M, Barranco A, Hernández-Jiménez E, Maetens M, Salgado R, Zafeirolou M, Pellegrini P, Venet D, Garaud S, Trinidad EM, Benítez S, Vuylsteke P, Polastro L, Wildiers H, Simon P, Lindeman G, Larsimont D, Van den Eynden G, Velghe C, Rothé F, Willard-Gallo K, Michiels S, Muñoz P, Walzer T, Planelles L, Penninger J, Azim HA Jr, Loi S, Piccart M, Sotiriou C, González-Suárez E. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. *Nature Commun*. 2020 Dec 10;11(1):6335.

46. Piccart M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causeret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, Kümmel S, Zoppi G, Thompson AM, Matos E, Zaman K, Hilbers F, Fumagalli D, Ravdin P, Knox S, Tryfonidis K, Peric A, Meulemans B, Bogaerts J, Cardoso F, Rutgers EJT. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. *Lancet Oncol*. 2021 Mar 12:S1470-2045(21)00007-3. doi: 10.1016/S1470-2045(21)00007-3.PMID: 33721561

47. Davey s, Lisa Bazzett-Matabele , Barati Monare , Alexander Seiphetleng , Gaobakwe Ramontshonyana , Vuylsteke P, Sebathu Chiyapo , Rebecca Luckett , Doreen Ramogola-Masire , Surbhi Grover. Gynecologic Cancer: New and Follow-Up Patient Appointments in Botswana During the COVID-19 Pandemic. *JCO Glob Oncol*. 2021 Apr;7:453-454. doi: 10.1200/GO.20.00590

48. van Walle L, Punie K, Van Eycken E, de Azambuja E, Wildiers H, Duhoux FP,Vuylsteke P, Barbeaux A, Van Damme N, Verhoeven D. Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study. *ESMO Open*. 2021 Aug;6(4):100207. doi:10.1016/j.esmoop.2021.100207. PMID: 34273808; PMCID:PMC8319479.

49. Turner NC, Balmaña J, Poncet C, Goulioti T, Tryfonidis K, Honkoop AH, Zoppi G, Razis E, Johannsson OT, Colleoni M, Tutt AN, Audeh W, Ignatiadis M, MailliezA, Trédan O, Musolino A, Vuylsteke P, Juan-Fita MJ, Macpherson IRJ, Kaufman B,Manso L, Goldstein LJ, Ellard SL, Lång I, Jen KY, Adam V, Litière S, Erban J,Cameron DA; BRAVO Steering Committee and the BRAVO investigators. Niraparib for Advanced Breast Cancer with Germline BRCA1and BRCA2 Mutations:the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. *Clin Cancer Res*.2021 Jul 22. doi: 10.1158/1078-0432.CCR-21-0310. PMID: 34301749.

50. I. Vergote MD, PhD, H. Denys MD, PhD, J. De Grève MD, PhD, C. Gennigens MD, PhD, K. Van de Vijver MD, PhD, J. Kerger MD, P. Vuylsteke MD, J-F. Baurain MD, PhD. Standard of care in 2021 for patients with ovarian cancer in belgium. *Belg j med oncol* Sept 2021;15(6):286-91

51. Gombos A, Venet D, Amey L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. *NPJ Breast Cancer*. 2021 Sep 21;7(1):125. doi: 10.1038/s41523-021-00331-8

52. Vergote I, Van Nieuwenhuysen E, De Waele S, Vuylsteke C, Lamot C, Van den Bulck H, Claes N, Graas MP, Debrock G, Spoormans I, Vuylsteke P, Honhon B, Verhoeven D, De Maeseneer D, Dirix L, Mebis J, Vroman P, Denys H, Martinez Mena C, Pelgrims G, Van Steenberghe M, van Gorp T, Gennigens C. Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*, ijgc-2021-003190. 21 Jan. 2022, doi:10.1136/ijgc-2021-00319

53. Rendle KA, Ramogola-Masire D, Monare B, Ogden SN, Toneff HK, Saia CA, Wainwright JV, Friebel-Klingner TM, Bazzett-Matabele L, Bhatia R, Bonner N, Ralefala TB, Vuylsteke P, Luckett R, Grover S. Patient perspectives on delays in cervical cancer screening and follow-up care in Botswana: a mixed methods study. *BMC Womens Health*. 2022 May 28;22(1):195. doi: 10.1186/s12905-022-01777-z.PMID: 35643491

54. Koole SN, Schouten PC, Hauke J, Kluin RJC, Nederlof P, Richters LK, Krebsbach G, Sikorska K, Alkemade M, Opdam M, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, Mom CH, Arts HJG, van Ham M, van Dam P, Vuylsteke P, Sanders J, Horlings HM, van de Vijver KK, Hahnen E, van Driel WJ, Schmutzler R, Sonke GS, Linn SC. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial. *Int J Cancer*. 2022 May 18. doi: 10.1002/ijc.34124.

55. Wildiers H, Meyskens T, Marréaud S, Lago LD, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Meulemans B, Sousa B, Poncet C, Brain E. Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. *Breast*. 2022 May 20;64:100-111. doi: 10.1016/j.breast.2022.05.004..PMID: 35636341

56. Dal Lago L, Uwimana AL, Coens C, Vuylsteke P, Curigliano G, Brouwers B, Jagiello-Gruszfeld A, Altintas S, Tryfonidis K, Poncet C, Bottomley A, Sousa B, Brain E, Wildiers H.J. Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. *Geriatr Oncol*. 2022 Jun;13(5):582-593. doi: 10.1016/j.jgo.2022.01.009.PMID: 35101364

57. De Jaeghere EA, Tuyaerts S, Van Nuffel AMT, Belmans A, Bogaerts K, Baiden-Amissah R, Lippens L, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Denys HG. Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study. *Cancer Immunol Immunother*. 2022 Aug 12. doi: 10.1007/s00262-022-03253-x. Online ahead of print.PMID: 35960332

58. Wu Q, Brouwers B, Dalmasso B, Kenis C, Vuylsteke P, Debrock G, Smeets A, Laenen A, Wildiers H, Hatse S. Dynamic alterations of immunosenescence-related genes in older women with breast cancer receiving chemotherapy: A prospective study. *Transl Oncol*. 2022 Nov;25:101527. doi: 10.1016/j.tranon.2022.101527. Epub 2022 Sep 3.PMID: 36067542

59. Friebe-Klingner TM, Bazzett-Matabele L, Ramogola-Masire D, Monare B, Ralefala TB, Seiphetlheng A, Ramontshonyana G, Vuylsteke P, Mitra N, Wiebe DJ, Rebbeck TR, McCarthy AM, Grover S. Distance to Multidisciplinary Team Clinic in Gaborone, Botswana, and Stage at Cervical Cancer Presentation for Women Living With and Without HIV. *JCO Glob Oncol*. 2022 Nov;8:e2200183. doi: 10.1200/GO.22.00183.
60. Grover S, George J, Tuli S, Lichter K, Bhatia R, Monare B, Chinniah G, Bazzett-Matabele L, Bvochora-Nsingo M, Chiyapo S, Balang D, Ralefala T, Vuylsteke P, Luckett R, Shin S, Zetola N, Ramogola-Masire D. Stage and outcomes of invasive cervical cancer patients in Botswana: A prospective cohort study from 2013 to 2020. *Gynecol Oncol Rep*. 2022 Oct 26;44:101094. doi: 10.1016/j.gore.2022.101094. eCollection 2022 Dec. PMID: 36337265
61. Koobotse MO, Zachariah M, Senabye B, Gobe I, Kadimo K, Nthontho KC, Mokomane M, Koto G, Phuthego T, Lekgetho H, Ndlovu A, Motswaledi M, Mbwinja A, Tawe L, Ramatlho P, Paganotti GM, Kyokunda L, Vuylsteke P, Grover S, Ramogola-Masire D, Kasvosve I. Bibliometric analysis of cancer research outputs in botswana between 2009 and 2021. *J Cancer Policy*. 2023 Jan 20:100405. doi: 10.1016/j.jcpo.2023.100405. Epub ahead of print. PMID: 36690157.
62. Grover S, Bhatia R, Friebe-Klingner TM, Mathoma A, Vuylsteke P, Khan S, Ralefala T, Tawe L, Bazzett-Matabele L, Monare B, Luckett R, Ramogola-Masire D. Cervical cancer screening in HIV-endemic countries: An urgent call for guideline change. *Cancer Treat Res Commun*. 2023 Jan 13;34:100682. doi: 10.1016/j.ctarc.2023.100682. Epub ahead of print. PMID: 36682141.
63. Davies L, Milner DA Jr, Shulman LN, Kyokunda L, Bedada A, Vuylsteke P, Masalu N, Jackson P, Jennings N, Odunlami A, Mtshali P, Dugan U. Analysis of Cancer Research Projects in Sub-Saharan Africa: A Quantitative Perspective on Unmet Needs and Opportunities. *JCO Glob Oncol*. 2023 Jun;9:e2200203. doi: 10.1200/GO.22.00203
64. Sharma K, Mayer T, Li S, Qureshi S, Farooq F, Vuylsteke P, Ralefala T, Marlink R. Advancing oncology drug therapies for sub-Saharan Africa. *PLOS Glob Public Health*. 2023 Jun 27;3(6):e0001653. doi: 10.1371/journal.pgph.0001653
65. Kambhampati A, Meghani K, Ndlovu N, Monare B, Mutimuri M, Bazzett-Matabele L, Vuylsteke P, Ketlametswe R, Ralefala T, Neugut AI, Jacobson JS, Vulpe H, Grover S. A Multi-Institutional Study of Barriers to Cervical Cancer Care in Sub-Saharan Africa. *Adv Radiat Oncol*. 2023 Apr 24;8(5):101257. doi: 10.1016/j.adro.2023.101257. eCollection 2023 Sep-Oct. PMID: 37408670
66. Lim KHJ, Westphalen CB, Berghoff AS, Cardone C, Connolly EA, Güven DC, Kfoury M, Kocakavuk E, Mandó P, Mariamidze E, Matikas A, Moutafi M, Oing C, Pihlak R, Punie K, Sánchez-Bayona R, Sobczuk P, Starzer AM, Tečić Vuger A, Zhu H, Cruz-Ordinario MVB, Altuna SC, Canário R, Vuylsteke P, Banerjee S, de Azambuja E, Cervantes A, Lambertini M, Mateo J, Amaral T. Young oncologists' perspective on the role and future of the clinician-scientist in oncology. *ESMO Open*. 2023 Aug 31;8(5):101625. doi: 10.1016/j.esmoop.2023.101625.
67. Grisham RN, Vergote I, Banerjee S, Drill E, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Cibula D, Moore KN, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churrua C, Kristensen G, Clamp A, Farley J, Iyer G, Ray-Coquard I, Monk BJ. Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer. *Clin Cancer Res*. 2023 Aug 15:CCR-23-0621. doi: 10.1158/1078-0432.CCR-23-0621.
68. Aronson SL, Lopez-Yurda M, Koole SN, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJ, van Gent MDJM, Arts HJG, van Ham MAPC, van Dam PA, Vuylsteke P, Aalbers AGJ, Verwaal VJ, van de Vijver KK, Aaronson NK, Sonke GS, van Driel WJ. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. *Lancet Oncol*. 2023 Sep 11:S1470-2045(23)00396-0. doi: 10.1016/S1470-2045(23)00396-0.
69. Lumley C, Batman S, Bazzett-Matabele L, Monare B, Bvochora-Nsingo M, Chiyapo S, Ketlametswe R, Mbulawa G, Seiphetlheng A, Ramontshonyane G, Ralefala T, Luckett R, Vuylsteke P, Grover S. Patterns of care and outcomes for endometrial and ovarian cancers in Botswana 2015-2021. *Gynecol Oncol Rep*. 2023 Aug 23;49:101262. doi: 10.1016/j.gore.2023.101262. eCollection 2023 Oct. PMID: 3769175
70. Grover S, MacDuffie E, Nsingo M, Lei X, Mehta P, Davey S, Urusaro S, Chiyapo S, Vuylsteke P, Monare B, Bazzett-Matabele L, Ralefala T, Luckett R, Ramogola-Masire D, Smith GL. Benchmarking of the Cervical Cancer Care Cascade and Survival Outcomes After Radiation Treatment in a Low- and Middle-Income Country Setting. *JCO Glob Oncol*. 2023 Sep;9:e2200397. doi: 10.1200/GO.22.00397. PMID: 37738538
71. Brandão M, Martins-Branco D, De Angelis C, Vuylsteke P, Gelber RD, van Damme N, van Walle L, Ferreira AR, Lambertini M, Poggio F, Verhoeven D, Barbeaux A, Duhoux FP, Wildiers H, Caballero C, Awada A, Piccart-Gebhart M, Punie K, de Azambuja E. Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium. *Breast Cancer Res Treat*. 2023 Oct 25. doi: 10.1007/s10549-023-07116-6. PMID: 37878152
72. Kirthana Sharma; Leyla Baghirova-Busang; Shaheen Abkenari; Godwill Gulubane; Charmi Rana; Peter Vuylsteke; Richard Marlink; Tendani Gaolathe; Tiny Masupe Breast Cancer Patient Experiences in the Botswana Health System: Is it time for Patient Navigators? *Journal of Cancer Policy*. 2023-10 | DOI: 10.1016/j.jcpo.2023.100449
73. Wildiers H, Armstrong A, Cuyper E, Dalenc F, Dirix L, Chan S, Marme F, Schröder CP, Huober J, Duhoux FP, Vuylsteke P, Jager A, Brain E, Kuemmel S, Pápai Z, Menke-van der Houven van Oordt CW, Perjesi L, Mueller C, Brignone C, Triebel F. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase 2b Trial. *Clin Cancer Res*. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-1173. PMID: 37939105
74. George J, Tuli S, Patel PP, Monare B, Ramogola-Masire D, Bazzett-Matabele L, Bvochora-Nsingo M, Chiyapo S, Ralefala T, Vuylsteke P, Rendle KA, Grover S. Delays in cervical cancer treatment initiation for patients living with or without HIV in Botswana: An observational cohort analysis (2015-2019). *Int J Radiat Oncol Biol Phys*. 2024 Mar 8: doi: 10.1016/j.ijrobp.2024.02.038.
75. Meghani K, Puri P, Bazzett-Matabele L, Vuylsteke P, Luckett R, Monare B, Chiyapo S, Ketlametswe R, Ralefala TB, Bvochora-Nsingo M, Zetola N, Ramogola-Masire D, Grover S. Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana. *Cancer*. 2024 Mar 26. doi: 10.1002/cncr.35289
76. Aronson SL, Walker C, Thijssen B, van de Vijver KK, Horlings HM, Sanders J, Alkemade M, Koole SN, Lopez-Yurda M, Lok CAR; Vuylsteke P OVHIPEC-1 Study Group; Rottenberg S, van Rheeën J, Sonke GS, van Driel WJ,

- Kester LA, Hahn K. Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1). *Br J Cancer*. 2024 Jun 12. doi: 10.1038/s41416-024-02731-6
77. Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, Bajpai J, Barrios CH, Bergh J, Bergsten-Nordström E, Biganzoli L, Cardoso MJ, Carey LA, Mac Gregor MC, Chidebe R, Cortés J, Curigliano G, Dent RA, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Franco Millan SX, Gilchrist J, Gligorov J, Gradishar WJ, Haidinger R, Harbeck N, Hu X, Kaur R, Kiely B, Kim SB, Kopikar S, Kuper-Hommel MJJ, Lecouvet FE, Mason G, Mertz SA, Mueller V, Myerson C, Neciosup S, Offersen BV, Ohno S, Pagani O, Partridge AH, Penault-Llorca F, Prat A, Rugo HS, Senkus E, Sledge GW, Swain SM, Thomssen C, Vorobiof DA, Vuylsteke P, Wiseman T, Xu B, Costa A, Norton L, Winer EP. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). *Breast*. 2024 May 28;76:103756. doi: 10.1016/j.breast.2024.103756
78. Graybill WS, Pardo Búrdalo B, O'Malley DM, Vergote I, Monk BJ, Auranen A, Copeland LJ, Sabbatini R, Herzog TJ, Follana P, Pothuri B, Braicu EI, McCormick C, Yubero A, Moore RG, Vuylsteke P, Raaschou-Jensen N, York W, Hartman J, González-Martín A. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study. *Int J Gynecol Cancer*. 2024 Jul 1;34(7):1041-1050. doi: 10.1136/ijgc-2024-005356.
79. Dykstra MP, Sadigh KS, Nkele I, Bvochora-Nsingo M, Martei YM, Wester J, Manyake K, Efstathiou JA, Vuylsteke P, Tapela NM, Dryden-Peterson S. Quality of Life Gain Following Treatment Among Breast Cancer Survivors With and Without HIV. *JCO Glob Oncol*. 2024 Aug;10:e2400110. doi: 10.1200/GO.24.00110
80. Swart NC, Lebelonyane R, Gutterman EM, Legwaila M, Friebe-Klingner TM, Antony R, Mayer T, Sharma K, Lall N, Kania B, Gaolathe T, Ralefala T, Ndaba V, Leselwa T, Vuylsteke P, Marlink R. Expanding Geographical Access to Cancer Care in Botswana: Current Status and Future Prospects. *JCO Glob Oncol*. 2024 Sep;10:e2400196. doi: 10.1200/GO.24.00196. Epub 2024 Sep 30.
81. Luckett R, Zhang BX, Gompers A, George J, Modest A, Bazzett-Matabele L, Vuylsteke P, Kula M, Monare B, Botha MH, Shapiro RL, Ramogola-Masire D, Grover S. High-grade cervical disease and cervical cancer in women aged 50 years and older compared with younger women: examining prevalence by HIV status in two large prospective cohorts in Botswana. *BMJ Open*. 2024 Oct 29;14(10):e089375. doi: 10.1136/bmjopen-2024-089375.PMID: 39477271 Free PMC article.
82. De Jaeghere EA, Hamerlinck H, Tuyaeerts S, Lippens L, Van Nuffel AMT, Baiden-Amisshah R, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Verhasselt B, Denys HG. Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial. *Gynecol Oncol*. 2024 Nov 7;191:275-286. doi: 10.1016/j.ygyno.2024.10.020. Online ahead of print.PMID: 39515198
83. Rendle KA, Ramogola-Masire D, Grover S; Vuylsteke P, Thibang Diphathla Collective. Implement Thibang Diphathla: a sequential multiple assignment randomized trial designed to increase timely adoption of cervical cancer treatment in Botswana. *Sci Commun* 2024 Nov 12;5(1):128. doi: 10.1186/s43058-024-00659-9.
84. Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alfía EM, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I; (Vuylsteke P) PAOLA-1/ENGOT-ov25 investigators. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial. *Ann Oncol*. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.10.828. Epub ahead of print. PMID: 39528049.Matsumoto T,
85. Wester JR, Wagner RB, Motladiile B, Nkele I, Chinyepi N, Makhema MJ, Friebe-Klingner TM, Vuylsteke P, Lockman S, Dryden-Peterson S, Kohler RE. Access to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana. *JCO Glob Oncol*. 2024 Dec;10:e2400180. doi: 10.1200/GO.24.00180. Epub 2024 Dec 12. PMID: 39666914.
86. Kania B, Sharma K, Ramathlo P, Vuylsteke P, Ndlovu A, Mayer T. Treatment approaches for prostate cancer in sub-Saharan Africa. *Transl Cancer Res*. 2024 Nov 30;13(11):6503-6510. doi: 10.21037/tcr-23-2289. Epub 2024 Jul 16. PMID: 39697741; PMCID: PMC11651809.
87. MacDuffie E, Kernell C, George J, Bvochora-Nsingo M, Vuylsteke P, Bazzett-Matabele L, Hughes K, Kassick M, Grover S. Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of locally advanced cervical cancer in Botswana. *Gynecol Oncol*. 2025 Feb 20;194:91-97. doi: 10.1016/j.ygyno.2025.02.002. Epub ahead of print. PMID: 39983352.
88. Grover S, Moorkanat GG, Ketlametswe R, Monare B, Puri P, Seiphethheng A, Ramontshonyana G, Friebe-Klingner TM, Bhatia R, Bvochora-Nsingo M, Chiyapo S, Bazzett-Matabele L, Vuylsteke P, Rendle KA. Impact of the COVID-19 Pandemic on Cervical Cancer Treatment Delays in Botswana. *JCO Glob Oncol*. 2025 May;11:e2400300. doi: 10.1200/GO-24-00300. Epub 2025 May9.PMID: 40344549
89. Martei YM, Gurram M, Mokokwe LT, Ngwako N, Kebuang K, Setlhako DI, Vuylsteke P, Bontswanetse B, Segadimo T, Mosepele M, Shulman LN, Barg F, Gaolebale BE. Baseline Distress and Effectiveness of Survivor Video Narratives on Cancer-Associated Distress in Botswana: A Pilot Study. *JCO Glob Oncol*. 2025 Jun;11:e2400474. doi: 10.1200/GO-24-00474. Epub 2025 Jun 18.PMID: 40532135
90. Brain E, Mir O, Bourbonloux E, Rigal O, Ferrero JM, Kirscher S, Allouache D, D'Hondt V, Savoye AM, Durando X, Duhoux FP, Venat-Bouvet L, Blot E, Canon JL, Rollot-Trad F, Bonnefoi H, Roque T, Lemonnier J, Latouche A, Henriques J, Lacroix-Triki M, Vernerey D, Vuylsteke P, GERICO&UCBG/Unicancer. Adjuvant chemotherapy and hormone therapy versus adjuvant hormone therapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial. *Lancet*. 2025 Aug 2;406(10502):489-500. doi: 10.1016/S0140-6736(25)00832-3. PMID: 40752909.
91. MacDuffie, E.; McCallister, C.; George, J.; Monare, B.; Ketlametswe, R.; Ramontshonyana, G.; Mmari, A.; Pharithi, M.; Mntande, L.; Vuylsteke, P.; et al. Assessing the impact of multidisciplinary team gynecological oncology care in Botswana: A potential model for low- and middle-income countries. 2025, 131, e70006, <https://doi.org/10.1002/cncr.70006>.
92. Johnson AT, Vuylsteke P (co first-author), Ntloedibe T, Mendez Reyes JE, John O, Wester JR, Chiao EY, Dryden-Peterson SL. Persistence to Adjuvant Endocrine Therapy for Breast Cancer in Botswana: An Observational Cohort Analysis. *Breast Care (Basel)*. 2025 Aug 4. doi: 10.1159/000547028. PMID: 41063761; PMCID: PMC12503760. . doi: 10.1159/000547028
93. Wagner RB, Wester JR, Motladiile B, Nkele I, Chinyepi N, Tshisimogo G,

Vuylsteke P, Lockman S, Dryden-Peterson S, Kohler RE. Quality of life among non-metastatic breast cancer survivors in Botswana. J Cancer Surviv. 2025 Sep 20. doi: 10.1007/s11764-025-01895-1. PMID: 40975726

94. Alexandru Eniu, Runcie CW Chidebe, Peter Vuylsteke, Mariana Chavez-MacGregor, Frederique Penault-Llorca, Gilberto Lopes, Matti Aapro, Silvia Neciosup, Nisha Pillay, Alexandra Lewis, Georgia Attfield, Fatima Cardoso. Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025– 2035 (Goal 9), The Breast, 104612

95. Papagiannis A, Majaj S, Duhoux FP, Agostinetti E, Stanciu AM, Vanhulst T, Buisseret L, Larsimont D, Veys I, Paesmans M, Hammer TB, Awada A, Ameye L, Rothe F, Madriles F, Cash TP, Salgado R, Willard-Gallo K, Sotiriou C, Vuylsteke P, Neven P, Ignatiadis M. Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study. Nat Commun. 2025 Nov 26. doi: 10.1038/s41467-025-66590-2. Epub ahead of print. PMID: 41298425

96. Vuylsteke P(presenter), M.Huizing,K.Petrakova, L.Fehrenbacher. PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC).September 2015; European Journal of Cancer 51(3):S265-S266 DOI: 10.1016/S0959-8049(16)30757-2. Oral Plenary presentation, ESMO congress, Vienna 2015

97. Vuylsteke P (presenter), Goeminne JC, Henry S, Vanhudenarde V, Willemart B, Marchettini P,Taylor D. Should Tumour Infiltrating Lymphocytes and PIK3Ca mutation be added as markers to the histology report for breast cancer? Oral Poster presentation, Narilis Conference, Namur, Belgium, 2016

98. I. Nkele, B. Baaitse , B. Motladiile1 , T. Neilan , T. Quinaglia , Z. Drobni , T. Ralefala , S. Dryden-Peterson, P. Vuylsteke. Risk of breast cancer understaging through standard clinical and radiographic staging in Botswana. Poster presentation, Annals of Oncology, ESMO Congress 2021, Paris. DOI:<https://doi.org/10.1016/j.annonc.2021.08.509>

99. Onalenna Sokwe, Amon Marwiro, Gontse Tshisimogo , Koziba Mookodi,Somesh Kumar , Tlotlo Ralefala, Maur Maccarthy, Peter Vuylsteke. Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot. ESMOOpen 8(1):101457. DOI: 10.1016/j.esmoop.2023.101457. Poster Presentation, ESMO Breast Congress Berlin

100. Migeotte Ariane, Ines Soares de Pinho, Ngwao Ngwako, Leselwa Tapologo, Lethloma Tebogo, Ralefala Tlotlo, Setlhako Irene, Swart Norman Carl, Khutjwe Joyce, Gaolathe Tendani, Lebelonyane Refeletswe, Keleapere Margaret Chalebgwa, Moanakwena Penelope, Marlink Richard, Sharma Kirthana, Peter Vuylsteke. Improving Access to Breast Cancer Diagnosis and Treatment through Navigation: Evaluation of a One Year Pilot Project in Botswana . Poster Presentation, Annals of Oncology, ESMO Congress Madrid, October 2023. Annals of Oncology,Vol. 34SupplementS938-S939

101. Peter Vuylsteke (presenter),S.Kutika Nyagabona,G.Nakigudde, O.Ginsburg,B.Aguilar, F.Cardoso. Management of patients with advanced breast cancer and HIV. Oral Presentation, Advanced Breast Cancer ABC7 Congress, Lisbon, October 2023, The Breast, Volume 71Supplement S25

102. Detournay A, Nguyen D, Mostmans Y., B en Mustapha S., Besse T., Vuylsteke P. Vulvar squamous cell carcinoma with paraneoplastic systemic sclerosis: Can radiotherapy be given safely? Poster Presentation, BSMO Annual Meeting, Feb 2025, BJMO

103. D.T. Nguyen, S. Lévy, A.J. Arroyo Salgado, L. Berte, G. Salem Wehbe, T. Besse-Hammer, M. Surquin, F. Benoit, P. Vuylsteke. Surgery omission in elderly patients with luminal breast cancer: Survival outcomes and associated geriatric factors. Annals of Oncology (2025) 10 (suppl_4): 1-13. 10.1016/esmoop/esmoop104705

BOOK CHAPTER AS AUTHOR/EDITOR

104. Global breast cancer initiative implementation framework: assessing, strengthening, and scaling up of services for the early detection and management of breast cancer, WHO GBCI Initiative, 118 pages, ISBN: 978-92-4-006598-7, March 7,2023.

105. Patient navigation for early detection, diagnosis, and treatment of breast cancer: technical brief, WHO GBCI Initiative, 56 pages, ISBN: 978-92-4-010095-4, Oct 11, 2024

Projects

Memberships

European Society of Medical Oncology (ESMO)

2017-2022: ESMO FACULTY member for Breast cancer.

2017-2019: ESMO National representative for Belgium.

2017-2019: ESMO Global Policy group member.

2005-to date: ESMO-membership

Board or Steering Committees

2025-to date: European Medicines Agency (EMA): core member for the Oncology SAG (Scientific Advisory Group)

2021- to date: WHO Global Breast Cancer Initiative (GBCI): steering comitee member (Leader for GBCI Pilar 3 workgroup on systemic treatment).

2021- to date: Board member of ICF: International Cancer Foundation

2021- to date: Trustee of CAB (Cancer Association of Botswana)

2021-to date: University of Botswana Internal Medicine departmental Board chair

2021-to date: Executive committee Member of Botsogo (Botswana Harvard Oncology Group)

2016- 2019: Steering committee member of EORTC Breast cancer group

2010-2019: Steering committee member of BGOG (Belgian Gynae-Oncological group)

2013-2019: Steering committee member of the "Salamon Foundation", offering cancer patient support in Belgium (transport for treatment, wellness support,...)

2011-2019 Steering Committee member of the SORMN Association, a firm of 21 specialists involved in Cancer Care in Namur, Belgium

Other Relevant Information